{"filing":{"accession_number":"0001628280-26-040038","cik":"0001636651","ticker":"OVID","company_name":"Ovid Therapeutics Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"ovid-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026040038/ovid-20260602.htm"},"events":[{"id":7287,"run_id":6397,"accession_number":"0001628280-26-040038","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Dr. Anna Greka as a Class III director of Ovid Therapeutics, effective June 15, 2026, following Board approval on May 29, 2026. The principal disclosed action is a person taking a role (director and committee member), making this an executive appointment. Dr. Greka's appointment is material as it represents a change in board composition and governance structure, and her credentials as a Harvard Medical School professor with significant biotech experience would be relevant to investor assessment of the company's leadership.","company_name":"Ovid Therapeutics Inc.","ticker":"OVID","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4121,"accession_number":"0001628280-26-040038","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Anna Greka as a Class III director of Ovid Therapeutics, effective June 15, 2026, following Board approval on May 29, 2026. The principal disclosed action is a person taking a role (director and committee member), making this an executive appointment. Dr. Greka's appointment is material as it represents a change in board composition and governance structure, and her credentials as a Harvard Medical School professor with significant biotech experience would be relevant to investor assessment of the company's leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:49:07.638479+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4121,"accession_number":"0001628280-26-040038","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Anna Greka as a Class III director of Ovid Therapeutics, effective June 15, 2026, following Board approval on May 29, 2026. The principal disclosed action is a person taking a role (director and committee member), making this an executive appointment. Dr. Greka's appointment is material as it represents a change in board composition and governance structure, and her credentials as a Harvard Medical School professor with significant biotech experience would be relevant to investor assessment of the company's leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:49:07.638479+00:00","company_name":"Ovid Therapeutics Inc.","ticker":"OVID","filing_date":"2026-06-03"}]}